Hyaluronic Acid Injection (Sodium Hyaluronate)

Adult administration

Administer 25 mg of Sodium Hyaluronate intra-articularly in the knee joint or shoulder (shoulder joint cavity, subacromial bursa, or biceps tendon sheath) once a week for 5 weeks. The frequency of administration can be appropriately adjusted based on symptoms.

This medication should not be used in patients who have had allergic reactions to this medication or its components. Since it is a drug injected directly into the joints, it should not be used if there is a skin disease or infection at the injection site. Caution is necessary for patients with liver dysfunction or a history of liver disease, as liver enzyme levels may become abnormal upon use of this medication. Patients with allergies to avian protein should also avoid using this medication. During treatment, serious allergic reactions like shock may occur, so patients should be closely monitored, and if any abnormal symptoms arise, treatment should be stopped immediately and appropriate care should be taken. Hypersensitive reactions such as swelling, redness, rash, hives, and itching may occur around the facial area, so if these symptoms appear, use should be discontinued and the hospital should be informed. Temporary pain, swelling, redness, warmth, severe pressure, and bruising may occur at the injection site, so this should be kept in mind. Occasionally, systemic symptoms such as nausea, vomiting, fever, and headache may also appear. In cases of severe inflammation in the joints, it is recommended to reduce the inflammation before using this medication, and stabilizing the injection site after injection will help. If the drug leaks outside the joint, pain may intensify, so it should be injected accurately within the joint. Patients with inflammatory arthritis such as rheumatoid arthritis or gout may experience temporary exacerbation of inflammation. Avoid vigorous exercise or long-duration weight-bearing activities for 48 hours after injection. Using this in conjunction with other intra-articular injection products has not been validated for safety and efficacy, thus is not recommended. Women who are pregnant or may become pregnant should only use this medication cautiously as its safety has not been sufficiently established. This medication can be transmitted through breast milk, so it is advisable to avoid use while breastfeeding. Safety has not been established for children, so should be used carefully only when necessary. Elderly patients may have weakened bodily functions, so greater caution is advised during administration. Aseptic conditions must be strictly maintained during injection, and if symptoms do not improve, treatment should be halted after five administrations. If there is fluid accumulation in the joints, it is advisable to remove it before injection. Intravenous administration is absolutely prohibited, and this medication is not suitable for use in the eyes. Due to the viscosity of the solution, care should be taken with the selection of the syringe and needle, and caution should be observed when withdrawing the solution from the ampoule. Use should occur swiftly after opening, and any remaining medication should be discarded. Using a local anesthetic before injection may help relieve pain.

Serious side effects

• Hives
• swelling (facial, eyelid, etc.)
• shock

Mild side effects

• Nausea
• vomiting
• fever
• headache
• facial flushing
• itching
• local pain
• swelling
• redness
• warmth

This medication is sensitive to light, so it should be stored in a sealed container that blocks light. Additionally, refrigeration is required to maintain the effectiveness of the drug. For export medications, they should be kept in a sealed container that blocks light, in a cool place below 25 degrees Celsius.

Appearance

A colorless, transparent, and viscous liquid contained in a glass or plastic tube (pre-filled syringe) sealed with rubber stoppers at both ends.

Package unit

2.5 milliliters/tube x 5